Rocket Pharmaceuticals (RCKT) Capital Leases (2020 - 2025)
Historic Capital Leases for Rocket Pharmaceuticals (RCKT) over the last 6 years, with Q3 2025 value amounting to $19.4 million.
- Rocket Pharmaceuticals' Capital Leases fell 3.61% to $19.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.4 million, marking a year-over-year decrease of 3.61%. This contributed to the annual value of $19.4 million for FY2024, which is 15.5% up from last year.
- According to the latest figures from Q3 2025, Rocket Pharmaceuticals' Capital Leases is $19.4 million, which was down 3.61% from $19.4 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Capital Leases ranged from a high of $19.4 million in Q4 2024 and a low of $19.0 million during Q1 2021
- Its 5-year average for Capital Leases is $19.3 million, with a median of $19.3 million in 2023.
- Per our database at Business Quant, Rocket Pharmaceuticals' Capital Leases surged by 93.36% in 2021 and then fell by 3.61% in 2025.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Capital Leases stood at $19.1 million in 2021, then increased by 0.65% to $19.3 million in 2022, then rose by 0.44% to $19.4 million in 2023, then rose by 0.16% to $19.4 million in 2024, then decreased by 0.04% to $19.4 million in 2025.
- Its Capital Leases was $19.4 million in Q3 2025, compared to $19.4 million in Q2 2025 and $19.4 million in Q1 2025.